Amphastar Pharmaceuticals Stock Forecast, Price & News

Amphastar Pharmaceuticals (NASDAQ:AMPH) Frequently Asked Questions

Is Amphastar Pharmaceuticals a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Amphastar Pharmaceuticals stock.
View analyst ratings for Amphastar Pharmaceuticals or view top-rated stocks.

How has Amphastar Pharmaceuticals' stock been impacted by Coronavirus?

Amphastar Pharmaceuticals' stock was trading at $15.30 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AMPH stock has increased by 65.8% and is now trading at $25.37.
View which stocks have been most impacted by COVID-19.

When is Amphastar Pharmaceuticals' next earnings date?

Amphastar Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, March 21st 2022.
View our earnings forecast for Amphastar Pharmaceuticals.

How were Amphastar Pharmaceuticals' earnings last quarter?

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) released its quarterly earnings data on Monday, November, 8th. The company reported $0.46 EPS for the quarter, beating the consensus estimate of $0.24 by $0.22. The firm had revenue of $112.20 million for the quarter, compared to analyst estimates of $103 million. Amphastar Pharmaceuticals had a trailing twelve-month return on equity of 12.28% and a net margin of 8.74%. During the same period in the prior year, the company earned $0.09 earnings per share.
View Amphastar Pharmaceuticals' earnings history.

What price target have analysts set for AMPH?

3 equities research analysts have issued 12-month price objectives for Amphastar Pharmaceuticals' shares. Their forecasts range from $20.00 to $28.00. On average, they anticipate Amphastar Pharmaceuticals' stock price to reach $23.67 in the next year. This suggests that the stock has a possible downside of 6.7%.
View analysts' price targets for Amphastar Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Amphastar Pharmaceuticals' key executives?

Amphastar Pharmaceuticals' management team includes the following people:

• Zi Ping Luo, Chairman, COO & Chief Scientist
• Yong Feng Zhang, President, Chief Executive & Scientific Officer
• William J. Peters, Chief Financial Officer, Treasurer & Executive VP (LinkedIn Profile)
• Rong Zhou, Executive Vice President-Production Center (LinkedIn Profile)
• Jacob Liawatidewi, Secretary & EVP-Corporate Administration Centre (LinkedIn Profile)

What is Jack Y. Zhang's approval rating as Amphastar Pharmaceuticals' CEO?

27 employees have rated Amphastar Pharmaceuticals CEO Jack Y. Zhang on Glassdoor.com. Jack Y. Zhang has an approval rating of 35% among Amphastar Pharmaceuticals' employees. This puts Jack Y. Zhang in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Amphastar Pharmaceuticals' key competitors?

Some companies that are related to Amphastar Pharmaceuticals include Ultragenyx Pharmaceutical (RARE), Ionis Pharmaceuticals (IONS), Blueprint Medicines (BPMC), CureVac (CVAC), Alkermes (ALKS), Cerevel Therapeutics (CERE), Galapagos (GLPG), ACADIA Pharmaceuticals (ACAD), Arvinas (ARVN), Apellis Pharmaceuticals (APLS), Karuna Therapeutics (KRTX), Intra-Cellular Therapies (ITCI), Hypera (HYPMY), OPKO Health (OPK) and Dicerna Pharmaceuticals (DRNA).
View all of AMPH's competitors.

What other stocks do shareholders of Amphastar Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), Exelixis (EXEL), CNX Resources (CNX), Immunomedics (IMMU), AbbVie (ABBV), Cellectis (CLLS), Clovis Oncology (CLVS) and Galectin Therapeutics (GALT).

What is Amphastar Pharmaceuticals' stock symbol?

Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."

Who are Amphastar Pharmaceuticals' major shareholders?

Amphastar Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Frontier Capital Management Co. LLC (0.53%), State of Alaska Department of Revenue (0.05%), Exchange Traded Concepts LLC (0.05%), Intelligence Driven Advisers LLC (0.03%), Diversified Trust Co (0.02%) and Veriti Management LLC (0.02%). Company insiders that own Amphastar Pharmaceuticals stock include David Maris, Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Richard K Prins, Richard Koo, Rong Zhou, William J Peters, William J Peters and Yakob Liawatidewi.
View institutional ownership trends for Amphastar Pharmaceuticals.

Which major investors are selling Amphastar Pharmaceuticals stock?

AMPH stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, and State of Alaska Department of Revenue. Company insiders that have sold Amphastar Pharmaceuticals company stock in the last year include Floyd F Petersen, Howard Lee, Jack Y Zhang, Michael A Zasloff, Richard K Prins, Richard Koo, Rong Zhou, William J Peters, and Yakob Liawatidewi.
View insider buying and selling activity for Amphastar Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Amphastar Pharmaceuticals stock?

AMPH stock was purchased by a variety of institutional investors in the last quarter, including Exchange Traded Concepts LLC, Intelligence Driven Advisers LLC, Diversified Trust Co, and Veriti Management LLC.
View insider buying and selling activity for Amphastar Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Amphastar Pharmaceuticals?

Shares of AMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amphastar Pharmaceuticals' stock price today?

One share of AMPH stock can currently be purchased for approximately $25.37.

How much money does Amphastar Pharmaceuticals make?

Amphastar Pharmaceuticals has a market capitalization of $1.21 billion and generates $349.85 million in revenue each year. The company earns $1.40 million in net income (profit) each year or $0.72 on an earnings per share basis.

How many employees does Amphastar Pharmaceuticals have?

Amphastar Pharmaceuticals employs 1,980 workers across the globe.

What is Amphastar Pharmaceuticals' official website?

The official website for Amphastar Pharmaceuticals is www.amphastar.com.

Where are Amphastar Pharmaceuticals' headquarters?

Amphastar Pharmaceuticals is headquartered at 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730.

How can I contact Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The company can be reached via phone at (909) 980-9484, via email at [email protected], or via fax at 909-980-8296.